Innovating to address unmet patient needs
The challenge of skin disease is immense, and many people live with conditions that can be difficult to treat effectively.
LEO Pharma is determined to change that, leading the efforts to deepen global understanding of these diseases, evolve our current treatment offerings, and forge partnerships with leading innovators.
Medical dermatology remains an area of significant untapped potential. We are building one of the most focused dermatology pipelines in the industry. Through a broad range of programmes, our pipeline comprises both early and late-stage assets in a strong mix of projects aimed at topical, oral, and injectable treatments.
- Approved in the EU, US, UK, Australia, South Korea, Canada, Switzerland and the UAE for Chronic Hand Eczema
- Approved in the EU and U.S. and additional regions for atopic dermatitis.
- Approved in the EU and U.S and additional regions for Generalized Pustular Psoriasis. LEO Pharma in-licensed Spesolimab from Boehringer Ingelheim on September 30, 2025.
- Partnership announced 11 January 2025: Gilead controls the global rights to oral STAT6 program and are in full control of the clinical development. LEO Pharma will have the option to co-commercialize oral programs for dermatology ex-US.
- LEO Pharma holds an exclusive license from Gilead for STAT6 topical products in dermatology.